Tvardi Therapeutics, Inc. (TVRD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.63 (+0.62%), Market cap $0.04B, 52-week low–high $2.85 ~ $42.98.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in
Financial statements, price targets, institutional (13F) holdings and related news for Tvardi Therapeutics, Inc. are updated in real time on BlackAll Trade.
Tvardi Therapeutics, Inc. trades at $1.63 (+0.62%). Real-time quotes and charts are available on BlackAll Trade.
Tvardi Therapeutics, Inc. has a market cap of about $0.04B.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcriptio